Our study lays the foundation for more comprehensive experimental study (in vitro, in vivo) on modulating the cell death drug targets FANCD2, NCOA4 (COAD), IKBKB, (GBM), and RHOA (GBM and SCLC), to improve the therapeutic avenues in cancer treatment. This evidence concerns the gene FANCD2 and small cell lung carcinoma.